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ABSTRACT Induction of persistent antibody responses by vaccination is generally
thought to depend on efﬁcient help by T follicular helper cells. Since the T helper
cell response to HIV Env may not be optimal, we explored the possibility of improv-
ing the HIV Env antibody response to virus-like particle (VLP) vaccines by recruiting
T helper cells induced by commonly used licensed vaccines to provide help for Env-
speciﬁc B cells. B cells speciﬁc for the surface protein of a VLP can internalize the
entire VLP and thus present peptides derived from the surface and core proteins on
their major histocompatibility complex class II (MHC-II) molecules. This allows T
helper cells speciﬁc for the core protein to provide intrastructural help for B cells
recognizing the surface protein. Consistently, priming mice with an adjuvanted Gag
protein vaccine enhanced the HIV Env antibody response to subsequent booster im-
munizations with HIV VLPs. To harness T helper cells induced by the licensed Teta-
nolpur vaccines, HIV VLPs that contained T helper cell epitopes of tetanus toxoid
were generated. Tetanol-immunized mice raised stronger antibody responses to im-
munizations with VLPs containing tetanus toxoid T helper cell epitopes but not to
VLPs lacking these epitopes. Depending on the priming immunization, the IgG sub-
type response to HIV Env after the VLP immunization could also be modiﬁed. Thus,
harnessing T helper cells induced by other vaccines appears to be a promising ap-
proach to improve the HIV Env antibody response to VLP vaccines.
IMPORTANCE Induction of HIV Env antibodies at sufﬁcient levels with optimal Fc ef-
fector functions for durable protection remains a challenge. Efﬁcient T cell help may
be essential to induce such a desirable antibody response. Here, we provide proof of
concept that T helper cells induced by a licensed vaccine can be harnessed to pro-
vide help for HIV Env-speciﬁc B cells and to modulate the Env-speciﬁc IgG subtype
response.
KEYWORDS intrastructural help, T helper cells, HIV, Env, antibody, vaccine, VLP,
IgG subtype
Virus-like particle (VLP) vaccines have been shown to be highly immunogenic and toprovide protection from a number of viral diseases (reviewed in reference 1). Due
to the repetitive nature of their surface proteins, VLPs can trigger cross-linking of B cell
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receptors (BCRs) speciﬁc for the surface protein, which may partially explain the good
antibody (Ab) responses observed after VLP immunization (2). Development of VLP
vaccines against HIV faces a number of challenges. The diversity of circulating HIV
strains requires Env immunogens that induce broadly reactive antibody responses to
the native Env spikes on the virion. Therefore, Env immunogen design is a major focus
of current HIV vaccine development efforts (reviewed in reference 3). In addition,
induction of HIV Env antibodies at levels high enough to provide durable protection
from HIV acquisition remains a challenge (4). Providing adequate T cell help may be a
critical step for the development of vaccines inducing long-lasting antibody responses
protecting from HIV acquisition. In mice, we observed that induction of primary
anti-Env antibody responses by VLP immunization depends on T helper cells (5).
However, T helper cell responses to HIV Env are generally weak during HIV infection (6),
and HIV Env antibody responses in human vaccinees seem to rapidly decline (7). We
previously showed that Gag-speciﬁc T helper cells induced by gene-based vaccines can
provide help for HIV Env-speciﬁc B cells after booster immunizations with VLPs (8, 9).
This intrastructural help (10–13) can be explained by uptake of entire VLPs by Env-
speciﬁc B cells and subsequent presentation of Gag- and Env-derived T helper cell
epitopes on major histocompatibility complex class II (MHC-II) molecules of the Env-
speciﬁc B cells (Fig. 1). We now extend these observations to adjuvanted protein
vaccines and provide proof of concept that T helper cells induced by a commonly used
licensed protein vaccine can also be harnessed to deliver help for Env antibody
responses. Thus, recruitment of preexisting T helper cells induced by licensed vaccines
seems to be a promising novel strategy to optimize antibody responses to surface
proteins of VLP vaccines.
RESULTS
Modulation of the HIV Env-speciﬁc antibody response by an adjuvanted HIV
Gag protein immunization. We previously observed that T helper cells induced by
DNA or adenoviral vector vaccines encoding Gag or GagPol provided intrastructural
help for Env antibody responses after VLP booster immunizations in mice (8, 9). To
explore whether an adjuvanted protein vaccine could similarly modulate the HIV Env
antibody response by intrastructural help, mice were ﬁrst immunized with recombinant
Gag protein adjuvanted with poly(ICLC), a Toll-like receptor 3 (TLR3) and MDA-5 ligand
(14). Poly(ICLC) has been shown to be a strong inducer of T helper cell responses in
mice (15) and nonhuman primates (16). Several reports (17, 18) also demonstrated that
poly(ICLC) induces strong CD4 T cell responses but weak CD8 T cell responses.
The Gag antibody response after a single immunization with the adjuvanted Gag
protein vaccine was compared to that after immunization with an HIV-Gag DNA vaccine
to deﬁne a suitable concentration of the adjuvant. Mice were primed with a constant
amount of Gag protein in the presence of increasing concentrations of poly(ICLC).
Three weeks after the immunization, Gag-speciﬁc antibody levels directly correlated
with the dose of the adjuvant. The minimal dose of poly(ICLC) required for signiﬁcant
FIG 1 Mechanism of intrastructural help. Env-speciﬁc B cells encountering HIV virions or VLPs take up the
entire particle in a BCR-dependent manner and present Env- and Gag-derived T helper cell epitopes on
their MHC-II molecules. Therefore, Gag-speciﬁc T helper cells can provide help to Env-speciﬁc B cells.
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enhancement of Gag-speciﬁc IgG1 and IgG2a antibody levels was 10 g (Fig. 2A). We
therefore selected this dose for all subsequent experiments. The adjuvanted Gag
protein and the Gag DNA vaccines also induced Gag-speciﬁc T helper cells producing
Th1 cytokines (Fig. 2B). Interestingly, the cytokine proﬁles differed between the two
groups. The response in the adjuvanted Gag group was dominated by tumor necrosis
factor alpha (TNF-), while a more balanced gamma interferon (IFN-) and TNF-
production was observed in the Gag DNA group (Fig. 2B).
To explore the extent to which Gag-speciﬁc T helper cells provide intrastructural
help, mice received two priming immunizations with different Gag immunogens or
controls prior to two booster immunizations with the same VLPs (Fig. 2C). After two
priming immunizations with the adjuvanted Gag protein vaccine, strong Gag-speciﬁc
IgG1 and IgG2a antibody responses that exceeded the ones induced by the Gag DNA
vaccine were observed (Fig. 2D). Nonadjuvanted Gag induced only a weak Gag-speciﬁc
IgG1 response. Looking at the HIV Env antibody responses after the two VLP booster
immunization, we noted that priming with adjuvanted Gag signiﬁcantly enhanced HIV
Env-speciﬁc IgG1 and IgG2a antibody levels, while Gag DNA priming enhanced only HIV
Env-speciﬁc IgG2a antibody responses (Fig. 2E).
Since Fc effector functions may depend more on the ratio of IgG subtypes than on
their absolute values, we also determined the ratio of HIV-1 Env-speciﬁc (IgG2a/IgG1)
antibodies. Mice that were primed by either HIV Gag DNA or adjuvanted HIV Gag
protein immunization had a signiﬁcantly enhanced ratio of HIV-1 Env-speciﬁc (IgG2a/
IgG1) antibodies (Fig. 2F), conﬁrming that intrastructural help can modulate IgG
subtype ratios.
Generation of VLPs containing FrC of TT. Having shown that an adjuvanted Gag
protein vaccine can provide intrastructural help for HIV Env antibody responses trig-
gered by a VLP vaccine, we asked whether T helper cells induced by a licensed protein
vaccine, such as Tetanol, could be harnessed to provide intrastructural help for HIV
VLPs. Since fragment C (FrC) of tetanus toxoid (TT) has been shown to efﬁciently
harness T cell help for antibody responses in the context of fusion proteins (19), we
inserted the coding sequence of fragment C of TT in frame between the genes for
matrix (MA) and capsid (CA) of Gag (Fig. 3A). Insertions at this site have been shown
previously to be compatible with particle formation and budding (33). Transient
cotransfection of the FrC-Gag and Env expression plasmids into 293T cells led to the
release of particles (FrC-VLP) that could be pelleted through a 35% sucrose cushion (Fig.
3B). Although the Env content of wild-type VLPs seemed to be higher, Env could also
be detected readily in the FrC-VLPs (Fig. 3B). Western blot analysis with antibodies to
Gag and fragment C of tetanus toxoid revealed that the FrC-Gag fusion protein
migrated at a molecular weight of approximately 105 kDa, while the parental Gag had
the expected molecular weight of 55 kDa (Fig. 3B).
Inﬂuence of Tetanol immunization on the Env-speciﬁc IgG responses to VLP
vaccines containing TT T helper cell epitopes. To explore the effect of Tetanol
immunization on the HIV Env antibody response to VLPs containing fragment C of TT,
BALB/c mice were immunized twice with Tetanol (weeks 0 and 4) prior to one or two
injections of VLPs containing fragment C. After the booster immunizations with VLPs
containing fragment C, there was a trend to higher Env IgG1 antibody responses in
Tetanol-primed mice receiving VLPs containing fragment C than in unprimed BALB/c
mice, although this difference did not reach statistical signiﬁcance (Fig. 3C). No increase
in Env-speciﬁc IgG2a antibody responses was observed. Since BALB/c mice were
reported to have a Th2 bias favoring IgG1 antibody responses, we also performed a
Tetanol prime (weeks 0 and 4) and VLP boost (week 8) experiment in BL/6 mice. A
strong increase in Env-speciﬁc IgG1 antibody levels was observed in BL/6 mice that had
received prior Tetanol immunizations, while there was no effect on Env-speciﬁc IgG2a
antibody levels (Fig. 3D). In both BALB/c and BL/6 mice, no Tetanol priming effect on
Env IgG responses was observed after boosting with VLPs lacking fragment C of TT (Fig.
3E and F).
Licensed Vaccines Improve HIV Env Antibody Responses Journal of Virology
July 2018 Volume 92 Issue 14 e00141-18 jvi.asm.org 3
FIG 2 Intrastructural help by Gag immunogens. (A) BALB/c mice (n  4 per group) were immunized once with 1 g Gag and
the indicated dose (g) of poly(ICLC) (pICLC) or with 25 g Gag DNA vaccine by i.m. DNA electroporation. Three weeks later,
the antibody responses against Gag were analyzed at 1:500 serum dilutions. Shown are the mean values with the SEM for
logarithmically transformed values for Gag IgG1 and IgG2a. *, P  0.05; **, P  0.01; ****, P  0.001 (vaccine groups versus
nonprimed; one-way ANOVA with Tukey’s posttest). (B) Gag-speciﬁc CD4 T cell responses were analyzed by intracellular
cytokine staining for the indicated cytokines 2 weeks after a single i.m. injection of 1 g Gag, 10 g poly(ICLC) (pICLC), or the
combination of Gag and pICLC or a single i.m. electroporation of 25 g of a Gag DNA vaccine into BALB/c mice. Shown are
the mean values with SEM for four animals per group (, P  0.05 versus PBS, Gag, and pICLC for IFN-; *, P  0.05 versus
PBS for IL-2; ##, P  0.001 versus PBS and pICLC for TNF-; #, P  0.05 versus Gag for TNF- [one-way ANOVA with Tukey’s
posttest]). (C) BALB/c mice (n  11 or 12 per group) were immunized at weeks 0 and 4 with 1 g Gag or 10 g pICLC alone
or in combination or with the Gag DNA vaccine. All primed and nonprimed mice were boosted at weeks 8 and 12 with the
same VLP preparation containing Env and Gag, and naive sera were taken 1 week before the ﬁrst immunization. (D) Antibody
responses to Gag at 3 weeks after the second priming immunization at a serum dilution of 1:1,000. Shown are the mean values
with SEM for 11 or 12 animals from two independent experiments. The dashed line represents the background of naive sera
for Gag antibodies. For IgG1, *, P  0.05 versus nonprimed; , P  0.001 versus nonprimed, Gag, pICLC, and Gag DNA
(one-way ANOVA with Tukey’s posttest). For IgG2a, ****, P  0.0001 versus nonprimed, Gag, and pICLC; , P  0.001 versus
Gag DNA (one-way ANOVA with Tukey’s posttest). (E) Env-speciﬁc antibody responses 2 weeks after the second VLP booster
immunization. Shown are the mean values with SEM for logarithmically transformed HIV Env antibody concentrations in 11
or 12 animals from two independent experiments. For IgG1, *, P  0.05 versus pICLC (Kruskal-Wallis test with Dunn’s posttest).
For IgG2a, **, P  0.01 versus nonprimed, Gag, and pICLC; , P  0.001 versus Gag and pICLC (Kruskal-Wallis test with
Dunn’s posttest). The dashed lower and upper lines represent the detection limits of the HIV Env-speciﬁc IgG2a and IgG1
antibody levels, respectively. (F) Env-speciﬁc IgG2a/IgG1 ratios 2 weeks after the second VLP immunization. The bars represent
the median of the ratios for all animals of each group that were positive for both Env-speciﬁc IgG1 and IgG2a antibodies (open
symbols). Samples that were under the limit of detection for IgG2a and/or IgG1 are shown by closed symbols. *, P  0.05; **,
P  0.01 (Kruskal-Wallis test with Dunn’s posttest; vaccine groups versus nonprimed).
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Inﬂuence of TT-speciﬁc CD4 T cells on the in vivo proliferative response of
Ag-speciﬁc B cells to VLPs containing TT T helper cell epitopes. To corroborate our
hypothesis that TT-speciﬁc CD4 T cells provided direct help to HIV-1 Env-speciﬁc B
cells, we used the hen egg lysozyme (HEL) model antigen (Ag) and established an in
vivo proliferation assay for antigen-speciﬁc B cell responses that are dependent on
TT-speciﬁc T helper cells (Fig. 4A to F). Injection of VLPs displaying HEL on their surface
into mice that received carboxyﬂuorescein succinimidyl ester (CFSE)-labeled naive
HEL-speciﬁc B cells 4 h prior to the VLP injection led to proliferation of the HEL-speciﬁc
FIG 3 Intrastructural help by tetanus toxoid-speciﬁc T helper cells. (A) Map of Gag expression plasmids encoding
wild-type Gag, an FrC-Gag fusion protein, or an p2D1-Gag fusion protein. (B) Western blot analyses of wild-type
VLPs (wt-VLP) and FrC-VLPs with antibodies detecting the indicated proteins. X, positions of lanes removed from
the Western blots. (C to F) Env-speciﬁc antibody responses in BALB/c mice primed twice with Tetanol and boosted
once or twice with FrC-VLPs (C), BL/6 mice primed twice with Tetanol and boosted once with FrC-VLPs (D), BALB/c
mice primed twice with Tetanol and boosted once or twice with wt-VLPs (E), and BL/6 mice primed twice with
Tetanol and boosted once with wt-VLPs (F). The dashed lines represent the background observed in naive animals.
Shown are the means and the SEM of logarithmically transformed RLU for 4 animals per group at a 1:250 serum
dilution (C and E) and for 6 animals per group at a 1:100 serum dilution (D and F). ***, P  0.001 (unpaired t test).
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B cells (Fig. 4G). Priming mice with Tetanol prior to transfer of CFSE-labeled HEL-speciﬁc
B cells and injection of VLPs containing HEL on their surface and fragment C inside
enhanced the proliferative response of the HEL-speciﬁc B cells in comparison to
nonprimed mice (Fig. 4G). Depletion of CD4 T cells abolished the enhancement of
HEL-speciﬁc B cell proliferation, while the T cell-independent proliferation of HEL-
speciﬁc B cells induced by HEL VLPs was maintained. The SW-HEL donor mice from
which the HEL-speciﬁc B cells are derived are on the wild-type RAG background, and
only up to 40% of the transferred CFSE-labeled B cells carry HEL BCR, while the rest
of the B cells have undergone VH gene replacement (21) and did not bind HEL on their
BCR (Fig. 4E). These HEL-negative B220 CFSE B cells did not proliferate in any of the
experimental groups (data not shown), conﬁrming the antigen-speciﬁc nature of the B
cell proliferation after VLP immunization. These results clearly demonstrate that the
initial proliferation of naive B cells speciﬁcally recognizing VLP surface proteins was
CD4 T cell independent. However, Tetanol-induced CD4 T cells were able to signif-
icantly increase this proliferation, indicating an effect of intrastructural help already on
the early steps of antigen-mediated primary B cell expansion. To exclude the possibility
that the proliferative response induced by the Tetanol immunization led to cell death,
we also analyzed the effect of Tetanol priming on the expansion of HEL B cells in
spleens on day 7 after HEL-VLP immunizations (Fig. 4H). Naive B cells from SW-HEL mice
were transferred into Tetanol-primed and nonprimed mice which were then immu-
FIG 4 Enhancement of the proliferative response of naive antigen-speciﬁc B cells by intrastructural help. (A) BL/6 mice were primed s.c. twice over a 4-week
interval with 10 l of Tetanol per animal. Ten days after the last Tetanol injection, CD4 cells were depleted. Two weeks after the last Tetanol injection, naive
B cells from SW-HEL mice were labeled with CFSE and adoptively transferred into nonprimed or Tetanol-primed mice with or without CD4 cell depletion. The
acceptor animals were injected i.v. with FrC-VLPs containing membrane-anchored HEL (HEL-VLP). Three days later, splenocytes of these mice and of untreated
controls were stained with Alexa 647-conjugated HEL and anti-B220–APC-eFluor780 antibody. (B to F) Gating strategy for the analysis of in vivo proliferating
CFSE HEL B220 B cells. (B) Gating on lymphoid cells according to their forward scatter and sideward scatter. (C) Elimination of doublets by FSC-A versus.
FSC-H gating. (D) A dump channel was used to exclude autoﬂuorescent cells among B220-positive cell singlets. (E) HEL- and CFSE-positive cells were selected.
(F) Gating on proliferating CFSE HEL B220 B cells. Representative data are shown. (G) The bars represent mean values of percent proliferating cells for each
experimental group; values for individual mice are also shown. ***, P  0.001 (one-way ANOVA with Tukey’s posttest). (H) The bars represent expansion of
HEL-speciﬁc B cells (percentage of HEL B220 B cells among the total B220 B cell population) in nonprimed and Tetanol-primed animals versus controls. **,
P  0.001; ***, P  0.001 (one-way ANOVA with Tukey’s posttest; vaccine groups versus control).
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nized with HEL-VLPs containing fragment C. As expected, priming with Tetanol led to
a signiﬁcant increase in the percentage of HEL B220 B cells in the spleen (Fig. 4H),
conﬁrming their expansion.
Improving the production of VLPs containing T helper cell epitopes of TT. Since
the yield of VLPs based on the FrC-Gag expression plasmid was low, we compared the
efﬁciency of VLP formation by FrC-Gag with that by wild-type Gag and a novel Gag
expression plasmid that only contained the p2 T helper cell epitope of fragment B and
domain 1 of fragment C (Fig. 3A). Wild-type VLPs, FrC-VLPs, and p2D1-VLPs were
prepared by cotransfection of the HIV Env expression plasmid with expression plasmids
for wild-type Gag, FrC-Gag, or p2D1-Gag, respectively. As expected from the calculated
molecular weight, the p2D1-Gag pelleted through a 35% sucrose cushion was detected
by Western blotting with antibodies to Gag and fragment C of tetanus toxoid (TT) at 80
kDa (Fig. 5A). Although additional weaker bands, presumably due to proteolytic
cleavage, could also be observed, the intensity of the p2D1-Gag band was substantially
stronger than that of the FrC-Gag band. Consistent with more efﬁcient particle forma-
tion, the Env content of p2D1-VLPs was also higher than the Env content of FrC-VLPs
FIG 5 Characterization of p2D1-VLP. (A) Wild-type VLPs (wt-VLP), FrC-VLPs, and p2D1-VLPs were analyzed by Western
blotting with an antiserum against gp120 of HIV Env ( Env), a monoclonal antibody against p24 of Gag ( Gag), and a
monoclonal antibody against FrC and p2D1 ( TT). (B to D) p2D1-VLPs containing or lacking Env (p2D1-VLPΔEnv) were
immunoprecipitated with 2G12 or mock treated (Mock IP). Precipitates were analyzed by Western blotting with the
antibodies described for panel A. Equal amounts of p2D1-VLPs that were used for the immunoprecipitation were analyzed
directly by SDS-PAGE (Input). The additional bands at 25 kDa in immunoprecipitation samples are due to protein G that
was coeluted from the beads.
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(Fig. 5A). To further conﬁrm incorporation of HIV Env into the VLPs, the HIV Env
expression plasmid was cotransfected with the p2D1-Gag expression plasmid. VLPs
were puriﬁed from the supernatant of transfected cells and immunoprecipitated with
the HIV Env antibody 2G12. Western blot analyses for HIV Env revealed the presence of
HIV Env in the precipitates (Fig. 5B). Coprecipitation of Gag (Fig. 5C), which also reacted
with an antiserum to fragment C (Fig. 5D), indicated that HIV Env, Gag, and fragment
C were part of the same VLPs. The speciﬁcity of the immunoprecipitation was con-
ﬁrmed using VLPs lacking Env (Fig. 5B to D). Based on the more efﬁcient particle
formation, p2D1-Gag was selected for all subsequent experiments.
Inﬂuence of the priming immunization on HIV Env-speciﬁc IgG subtype re-
sponses to VLP vaccines containing T helper cell epitopes of heterologous vaccine
antigens. The results shown in Fig. 2F indicated that after priming with either adju-
vanted Gag protein or Gag DNA, intrastructural help increased the IgG2a/IgG1 ratio of
anti-HIV Env antibodies after the VLP immunization. In contrast, priming with Tetanol
enhanced only the HIV Env IgG1 antibody responses to FrC-VLP immunizations (Fig. 3C
and D). To further conﬁrm that the HIV Env-speciﬁc IgG subtype response was depen-
dent on the type of T helper cells mediating intrastructural help, we compared the
effects of Tetanol priming on the HIV Env antibody responses to VLPs containing
(p2D1-VLPs) or lacking (wt-VLPs) the p2D1 fragment. To reveal whether the formulation
and/or the nature of the antigen can modulate the IgG subtype response, we also
included tetanus toxoid and Gag DNA vaccines for priming (Fig. 6A).
Priming with Tetanol or TT DNA enhanced HIV Env-speciﬁc antibody levels in
response to p2D1-VLPs only, while the Gag DNA priming immunizations modulated HIV
Env antibody responses to both types of VLP vaccines to similar extents (Fig. 6B to F).
Interestingly, the HIV Env IgG subtype response to the same p2D1-VLP booster immu-
nizations clearly differed for the different priming immunizations (Fig. 6C to F). Priming
with Tetanol signiﬁcantly enhanced only HIV Env IgG1 antibody levels, while priming
with TT DNA enhanced IgG1, IgG2a, and IgG2b antibody levels. Priming with Gag DNA
led to an approximately 2,000-fold-higher mean Env-speciﬁc IgG2a antibody levels in
comparison to those in the nonprimed groups (Fig. 6D), while HIV Env IgG1 antibody
levels increased 50- to 100-fold (Fig. 6C).
To correlate the differential IgG subtype responses to differences in T helper cells
mediating intrastructural help, TT-speciﬁc CD4 T cell responses were characterized
after the priming immunization. Enzyme-linked immunosorbent spot (ELISPOT) analy-
ses and intracellular cytokine staining (ICS) after stimulation with the MHC-II-
restricted peptides p30 and p2 revealed induction of T helper cells producing IFN-
(Fig. 7A and B), which showed a trend of being more pronounced in the TT DNA
vaccine group. For other Th1 cytokines (TNF- and interleukin-2 [IL-2]), no differ-
ence between the two groups was observed (data not shown). In contrast, secretion
of the Th2 cytokines IL-4 and IL-5, could be detected only in Tetanol-immunized
animals (Fig. 7C and D).
Inﬂuence of Tetanol priming on the quality of the HIV Env antibody response
to VLP vaccines containing TT T helper cell epitopes. To further characterize the
effect of Tetanol priming on the quality of the antibody response, we analyzed
Fc-effector functions of HIV Env-speciﬁc antibodies 4 weeks after the second p2D1-VLP
booster immunization by reporter cell-based activation assays for Fc-RII, Fc-RIII, and
Fc-RIV (9). Sera from Tetanol-primed and p2D1-VLP-boosted mice led to a stronger
activation of all three Fc- receptors than with sera from mice only receiving the
p2D1-VLP immunizations, although these differences did not reach statistical signiﬁ-
cance (Fig. 8A to C).
To exclude that intrastructural help only transiently enhances antibody responses, a
10-week serological follow-up was also performed. Clearly, HIV Env-speciﬁc IgG1 anti-
body levels induced by p2D1-VLP immunization continued to be signiﬁcantly higher in
Tetanol-primed animals than in nonprimed controls (Fig. 8D).
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DISCUSSION
Similar to the case with gene-based vaccines encoding Gag (8, 9), the adjuvanted
Gag protein vaccine also induced T helper cells at levels sufﬁcient to provide intra-
structural help. However, for the protein vaccine this clearly required a strong adjuvant,
such as poly(ICLC). Extending the concept of intrastructural help from virus-speciﬁc T
helper cells, the results also constitute proof of concept for the strategy that T helper
cells induced by licensed vaccines can be harnessed to provide help for B cell responses
induced by VLP vaccines. The observation that the enhancement of antibody responses
to HIV Env by prior immunization with tetanus vaccines is entirely dependent on the
incorporation of tetanus toxoid-derived protein fragments into the VLP indicates that
it is not a general modiﬁcation of the inﬂammatory milieu during priming that persists
and mediates the modulation of the Env antibody response at the time of the VLP
FIG 6 Requirements for the modulation of the Env-speciﬁc IgG subtype response by intrastructural help. (A) BALB/c mice were immunized at
weeks 0 and 4 with Tetanol or DNA vaccines expressing tetanus toxoid or HIV Gag. All primed and nonprimed mice were boosted at weeks 8
and 12 with p2D1-VLPs or wild-type VLPs (wt-VLP). (B) Total Env-speciﬁc antibody concentrations in sera of mice primed with the indicated
immunogens 2 weeks after the second immunization with the indicated VLPs. Shown are the mean values with SEM of logarithmically
transformed HIV Env antibody concentrations in the sera of 12 to 18 animals per group from three independent experiments. *, P  0.05; **,
P  0.01, ***, P  0.001; ****, P  0.0001 (Kruskal-Wallis test with Dunn’s posttest; vaccine groups versus nonprimed). (C to F) Env speciﬁc IgG1
(C), IgG2a (D), IgG2b (E), and IgG3 (F) subtypes at 2 weeks after the second VLP immunization in animals boosted with p2D1-VLPs versus those
boosted with wt-VLPs. Shown are the mean values with SEM of logarithmically transformed concentrations of Env-speciﬁc IgG subtypes in sera
of 12 to 18 animals per group from three independent experiments. *, P  0.05; **, P  0.01, ***, P  0.001; ****, P  0.0001 (Kruskal-Wallis test
with Dunn’s posttest; vaccine groups versus nonprimed). (B, D, and E) The dashed lines represent the background values for naive sera. (C and
F) The background for naive sera lies on x axis at a value of 1.
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immunization. Consistently, depletion of CD4 T cells abolished the enhancement of
the proliferation of BCR-transgenic B cells speciﬁc for the model surface antigen of the
VLP by the Tetanol priming immunization.
Interestingly, both the antigen and the type of the priming immunization affected
the IgG subtype responses to HIV Env after the VLP immunization (Fig. 2 and 6). Tetanol
priming strongly enhanced the IgG1 Env antibody response and had no effect on the
anti-Env IgG2a, IgG2b, and IgG3 responses. Priming with a DNA vaccine encoding
tetanus toxoid fragment C led to a strong increase in IgG1 and a modest increase in
IgG2a and IgG2b responses to HIV Env. These IgG subclass distributions may reﬂect the
Th1/Th2 cytokine proﬁle of the antigen-speciﬁc CD4 T cells induced by priming.
Priming with Tetanol raised TT-speciﬁc CD4 T cells with a prominent Th2 phenotype.
Intrastructural help by these T helper cells during the VLP booster immunizations may
trigger expansion of B cells secreting Env-speciﬁc IgG1 and block class switching to
other IgG subtypes. On the contrary, TT DNA immunization induced tetanus-speciﬁc
CD4 T cells with a Th1-dominated phenotype most likely imprinting the Th1 pheno-
type to Env-speciﬁc B cells during the VLP booster immunizations (Fig. 7). The differ-
ence in the IgG subtype responses may directly affect Fc effector functions of the HIV
Env-speciﬁc antibodies, as observed previously (9). In the current study, intrastructural
help also enhanced the Fc effector function of the immune sera (Fig. 8A to C). Whether
this is due to higher overall level of HIV-1 Env-speciﬁc antibodies, changes in the ratio
of IgG subtypes, or differences in the glycosylation of the antibodies, remains to be
determined. Intrastructural help provided by Tetanol priming also resulted in a long-
FIG 7 Characterization of tetanus toxoid-speciﬁc cellular immune responses. BALB/c mice were immu-
nized i.m. once with PBS, Tetanol, or TT DNA. (A) TT-speciﬁc T cell responses 2 weeks after immunization
as determined by an IFN- ELISPOT assay with splenocytes stimulated with MHC-II-restricted p2 and p30
T helper peptides derived from TT. Shown are the mean values with SEM of spot-forming cells (SFC)
producing IFN- per 200,000 splenocytes for 8 animals per group out of two independent experiments. **,
P 0.01 (one-way ANOVA with Tukey’s posttest; vaccine groups versus PBS). (B) Percentage of splenic CD4
T cells cell producing IFN- after in vitro stimulation with p2 and p30 T helper peptides as measured by
intracellular cytokine staining. Mice (6 per group) were sacriﬁced 2 weeks after immunization. The cells were
stained for surface expression of CD4 and for intracellular expression of IFN-. The background values for
unstimulated cultures were subtracted. Shown are the mean values with SEM. *, P  0.05 (one-way ANOVA
with Tukey’s posttest; vaccine groups versus PBS). (C and D) Tetanus-speciﬁc IL-4 (C) and IL-5 (D) cytokine
secretion as determined by ELISA. Two weeks after immunization, splenocytes were stimulated with p2 and
p30 T helper peptides for 48 h. Themean values with SEM for 10 animals out of two independent experiments
are shown. *, P  0.05 (Tetanol versus PBS); **, P  0.01 (Tetanol versus TT DNA).
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lasting increase of the IgG1-dominated humoral immune response (Fig. 8D), suggesting
formation of long-lived plasma cells.
The applicability of intrastructural help in humans will critically depend on the
efﬁcient incorporation of protein fragments of licensed vaccines into the VLPs. As
shown by the inefﬁcient particle formation by FrC-Gag, the size of the fragment that
can be incorporated and/or its folding may be limiting. Therefore, it may be advanta-
geous to incorporate linear T helper cell epitopes rather than entire protein domains.
However, the allelic variation of MHC-II in the human population may require the
identiﬁcation of MHC-II epitopes to which many individuals raise T helper cell responses
or the incorporation of a panel of T helper cell epitopes. The use of promiscuous or
universal T helper epitopes that are binding on a broad range of MHC-II human alleles
might be an elegant solution to overcome this problem. The tetanus toxoid sequence
even offers two of such epitopes: p2 and p30 (22). Although each of the epitopes
demonstrates MHC-II binding on multiple MHC-II alleles among different species (from
mouse to human), helper T cell activity might strongly vary between the alleles (23–25).
Our observation that VLPs containing FrC with only one epitope (p30) were more
potent in BL/6 (H-2b) than in BALB/c (H-2d) mice (Fig. 3) is consistent with previous
reports (23). Reduction of total FrC size with additional incorporation of the second
universal epitope (p2) led to efﬁcient particle formation and improved humoral im-
mune responses in BALB/c mice (Fig. 6). Since each HIV particle contains approximately
2,000 Gag molecules, we assume a similar number of molecules of the T helper cell
FIG 8 Fc receptor activation assays and durability of the humoral immune response. BALB/c mice (6 per
group) were immunized twice at weeks 0 and 4 with Tetanol. Primed and nonprimed mice were boosted
at weeks 8 and 12 with p2D1-VLPs. (A to C) FcR activation by Env-speciﬁc Abs from sera taken 2 weeks
after the second VLP immunization using FcRII (A), FcRIII (B), or FcRIV (C) reporter cell lines secreting
IL-2. Background values from parental P815 cells not expressing Env were subtracted from the values
generated with P815Env cells to obtain the Env-speciﬁc Fc receptor activation. Shown are the mean IL-2
concentrations with SEM for 6 immune sera per group at a 1:100 dilution. *, P  0.05 (Tetanol-primed
versus nonprimed; unpaired t test). (D) Env IgG1 antibody levels were monitored for 10 weeks after the
second VLP immunization. Shown are the mean values with SEM of logarithmically transformed RLUs in
the sera of 6 animals per group (*, P  0.05; **, P  0.01, Tetanol-primed versus nonprimed, one-way
ANOVA with Tukey’s posttest).
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epitopes. However, the precise number of epitope molecules required for efﬁcient
intrastructural help remains to be determined. The merit of incorporating protein
fragments derived from the tetanus toxoid is that most people have been previously
vaccinated with Tetanol and therefore are likely to have preexisting memory T cells.
Follow-up studies will explore whether preexisting memory T cells can be directly
recruited by intrastructural help or whether Tetanol booster immunizations are re-
quired prior to the VLP immunizations. However, given the fact that the type and
persistence of antibody responses are thought to be largely regulated by T helper cells,
the intrastructural help approach seems to offer plenty of opportunities to improve the
antibody response to VLP vaccines.
MATERIALS AND METHODS
Cell lines, plasmids, and VLP preparation. HEK293T cells were cultured in Dulbecco’s modiﬁed
Eagle medium (DMEM) (Life Technologies, Darmstadt, Germany) with 10% heat-inactivated fetal calf
serum (FCS) (Life Technologies, Darmstadt, Germany) and 250 g/ml gentamicin (Applichem, Darmstadt,
Germany). Gag and p2D1-Gag expression plasmids were constructed by inserting the coding sequence
for fragment C (FrC) (amino acids [aa] 865 to 1316 of tetanus toxoid [TT] according to GenBank entry
number AAA23282.1) (23, 26, 27) or for the p2D1 fragment spanning the promiscuous Th epitope p2
(QYIKANSKFIGITE) and domain 1 of FrC (FrCD1) (aa 865 to 1120 according to GenBank entry number
AAA23282.1) by overlap extension PCR between the 3= codons (DTGHSSQ) of matrix (MA) and the 5=
codons (VSQNYPI) of capsid (CA) of the HgSyn expression plasmid (28). The plasmids HgSyn (a codon-
optimized HIV Gag expression plasmid) (28), pConBgp140GCD (encoding codon-optimized HIV-Env clade
B consensus sequence aa 1 to 703 of GenBank entry number ABG67916.1 fused to the intracellular
domain of vesicular stomatitis virus G [VSV-G] [aa 97 to 122 of GenBank entry number: CAA24524.1]) (8,
29), and pC-HEL-TM (encoding the membrane-anchored form of HEL) (20) have been described previ-
ously. All plasmids were prepared with the NucleoBond Xtra Maxi EF or the PC10000 EF kit (Macherey-
Nagel, Dueren, Germany). VLPs were prepared as described previously with slight modiﬁcations (8, 30).
Brieﬂy, 293T cells were cotransfected with 30 g of one of the Gag expression plasmids HgSyn, FrC-Gag,
or p2D1-Gag and 30 g pConBgp140GC/D to generate wild-type VLPs, FrC-VLPs, and p2D1-VLPs,
respectively. HEL-VLPs containing HEL on their surfaces and FrC-Gag inside were produced by cotrans-
fection of 30 g of FrC-Gag and 30 g of pC-HEL-TM. Transfections were performed in 175-cm2 ﬂasks
(Greiner Bio One, Frickenhausen, Germany) with 1 g polyethylenimine per 1 g DNA. At 6 h posttrans-
fection, the medium was replaced with fresh DMEM free of FCS and containing only 1% gentamicin
(Applichem) and 1% GlutaMAX (Life Technologies). Two days later, VLPs were puriﬁed from the
supernatant of transfected cells by ultracentrifugation through a 35% sucrose cushion for 4 h at
90,000  g and 4°C. Finally, the puriﬁed VLPs were resuspended in sterile phosphate-buffered saline
(PBS) and stored at 80°C until further use. To determine the amount of Env and Gag in the VLP
preparations, high-binding microtiter plates (Greiner Bio One) were coated with the puriﬁed VLPs or
serial dilutions of known amounts of p55 Gag (31) or HIV gp120 (HIV-1 IIIB; NIH Reference and Reagent
Program) as standards. The amounts of p55 and HIV gp120 from the VLP preparations bound to the
microtiter plate were then determined using an anti-HIV-1 p24 monoclonal antibody (183-H12-5C; NIH
AIDS Reference and Reagent Program), the monoclonal gp120 antibody 2G12 (Polymun, Klosterneuberg,
Austria), and matched horseradish peroxidase (HRP)-conjugated secondary antibody reagents. The
endotoxin levels of the immunogens were determined with the Limulus amebocyte lysate assay
(QCL-1000; Cambrex, Walkersville, MD) to be below 0.1 unit per injection dose.
Immune precipitation of p2D1-VLPs. To show that the p2D1-VLPs incorporate Env, Gag, and the
p2D1 fragment of TT into the same particles, we performed an immune precipitation with p2D1-VLPs as
described before (9). To this end, we coated 50 l protein G Dynabeads (Invitrogen, Life Technologies)
with 12 g monoclonal human anti-Env Ab 2G12 (Polymun, Klosterneuburg, Austria) in PBS plus 0.05%
Tween 20 (PBS-T) for 30 min at room temperature. After removal of excess 2G12 and washing steps with
PBS-T and PBS, we incubated the Dynabeads with p2D1-VLPs containing or lacking Env for 30 min at
room temperature. Following extensive washing with PBS, bound VLPs were eluted with reducing SDS
sample buffer by boiling for 5 min at 70°C and analyzed by Western blotting. HIV-1 Env was detected
with a polyclonal goat anti-gp120 Ab (Acris, Herford, Germany), Gag proteins with a monoclonal murine
anti-p24 Ab (183-H12-5C; National Institutes of Health AIDS Reagent Program), and p2D1 and FrC with
a polyclonal antiserum against TT (POL 016 anti-tetanus toxin; Statens Serum Institute, Copenhagen,
Denmark) (32), with HRP-conjugated secondary antibodies P0449, P0447, and P0399 (DakoCytomation,
Glostrup, Denmark), respectively.
Mice and immunizations. BALB/cJRj (BALB/c) and C57BL/6J (BL/6) mice (6 to 8 weeks old) were
purchased from Janvier Laboratories (Saint-Berthevin, France), and 12-week-old SW-HEL mice from
in-house breeding were donors for HEL-speciﬁc B cells for adoptive transfer experiments. All mice were
housed in individual ventilated cages in accordance with the national law and institutional guidelines at
the animal facility of the Faculty of Medicine, Ruhr University Bochum (Bochum, Germany). For the DNA
immunization, the animals were anesthetized by intraperitoneal (i.p.) injection of 100 mg/kg body weight
ketamine (CP-Pharma, Burgdorf, Germany) and 15 mg/kg body weight xylazine (CP-Pharma). The TriGrid
electrode array (Ichor Medical, San Diego, CA) with 2.5-mm electrode spacing bearing the centered
injection needle was inserted into the shaved hind legs of the mice (23). A volume of 50 l PBS
containing 30 g plasmid DNA was injected intramuscularly (i.m.) into the gastrocnemius muscle of each
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hind leg, which was immediately followed by the local application of electrical signals of 63-V amplitude
and 40-ms total duration. The VLPs were diluted in sterile PBS. All animals received 400 ng of Env per
immunization in a total volume of 100 l by subcutaneous (s.c.) injection distributed to both hind
footpads. A volume of 50 l PBS containing 1 g of Gag protein (p55) (31) alone or in combination with
0.3, 1, 3, or 10 g poly(ICLC) (Hiltonol-Oncovir, Inc.) was injected i.m. into each hind leg. For Tetanol
immunization, mice received a volume of 100 l PBS containing 10 l Tetanolpur (Novartis Vaccines and
Diagnostics, Marburg, Germany) by i.m. injection distributed to both hind legs.
Characterization of cellular immune responses. HIV Gag-speciﬁc CD4 T cell responses and
tetanus-speciﬁc CD4 T cell responses in spleens from mice were determined by intracellular cytokine
staining (ICS), cytokine-speciﬁc enzyme-linked immunosorbent assay (ELISA) as described before (9), and
IFN- ELISPOT. To this end, mice were sacriﬁced 2 weeks after a single immunization, the spleens were
removed, and single-cell suspensions were prepared using a 70-m cell strainer (BD Biosciences,
Heidelberg, Germany). After red blood cell (RBC) lysis, splenocytes were resuspended at 107 cells/ml in
RPMI 1640 supplemented with 10% heat-inactivated FCS, 1% penicillin-streptomycin, 10 mol HEPES,
and 4 mol L-glutamine (all from Life Technologies, Thermo Fisher Scientiﬁc) and 50 mol
-mercaptoethanol. For ICS, 106 splenocytes/well were seeded in a 96-well U-bottom microtiter plate
(Nunc; Thermo Fisher Scientiﬁc) and stimulated with 5 g/ml MHC-II-restricted peptides PVGEIYKRWIIL
and SPEVIPMFSALSEGA for HIV-1 Gag or 2 g/ml MHC-II-restricted peptides p2 (QYIKANSKFIGITELK) and
p30 (FNNFTVSFWLRVPKVSASHLE) for tetanus toxoid in the presence of 2 g/ml anti-CD28 (37.51; Life
Technologies, Thermo Fisher Scientiﬁc) and 2 mol monensin for 6 h at 37°C in a humidiﬁed 5%
CO2atmosphere. After stimulation, the cells were surface stained with anti-mouse CD4 peridinin chlo-
rophyll protein (PerCP)–eFluor710 (RM4-5) and ﬁxable viability dye eFluor780 (both from Life Technol-
ogies, Thermo Fisher Scientiﬁc). Following ﬁxation with 2% paraformaldehyde, cells were permeabilized
with 0.5% saponin in the presence of 1.7 g/ml anti-mouse CD16/CD32 (93; Life Technologies, Thermo
Fisher Scientiﬁc) and subsequently stained with anti-mouse TNF-–phycoerythrin (PE)-Cy7 (MP6-XT22)
and anti-mouse IFN-–PE (XMG1.2) (both from Life Technologies, Thermo Fisher Scientiﬁc) and anti-
mouse IL-2–allophycocyanin (APC) (JES6-5H4; Life Technologies, Thermo Fisher Scientiﬁc). Data were
acquired on an FACSCanto II (BD Biosciences) and analyzed with FlowJo (Tree Star, Ashland, OR, USA).
The gating strategy was reported previously (9). For the cytokine-speciﬁc ELISA, 5  106 cells/well were
seeded into 48-well plates and stimulated with 2 g/ml MHC-II-restricted peptides of tetanus toxoid (p2
and p30) in the presence of 2 g/ml anti-CD28 (37.51; Life Technologies, Thermo Fisher Scientiﬁc) for 48
h at 37°C in a humidiﬁed 5% CO2 atmosphere. After the stimulation, the supernatants were analyzed for
the presence of IL-4 and IL-5 with the cytokine-speciﬁc Ready-SET-Go ELISA (Life Technologies, Thermo
Fisher Scientiﬁc) according to the manufacturer’s protocol. For ELISPOT assay, IFN- responses were
detected with a mouse IFN- ELISPOT kit (88-7384; Life Technologies, Thermo Fisher Scientiﬁc). Brieﬂy,
96-well Multiscreen-IP ﬁlter plates (Millipore) were pretreated with 20 l of 70% methanol for 30 to 60
s and then washed three times in PBS (Ca2/Mg2 free), followed by coating with 100 l of capture
antibody. The plates were incubated overnight at 4°C. Excess coating antibody was removed, and plates
were washed 2 times with 200 l of ELISA/ELISPOT coating buffer (Life Technologies, Thermo Fisher
Scientiﬁc) and then were blocked in complete RPMI 1640 medium for 1 h at 37°C before cells were added.
Medium was removed from the plates, splenocytes in single-cell suspension were added at 2  105 cells
in duplicates to the wells, and then the cells were stimulated by tetanus p2 and p30 peptides at a ﬁnal
concentration of 2 g/ml. Wells containing complete RPMI 1640 medium and 10% dimethyl sulfoxide
(DMSO) (as in peptide-stimulated cultures) served as negative controls. Plates were incubated at 37°C for
72 h and then washed 3 times with ELISA/ELISPOT washing buffer. Subsequently, 100 l of biotinylated
detection antibody was added to each well. Plates were then incubated at room temperature for 2 h
before washing 4 times with ELISA/ELISPOT washing buffer. Next, 100 l Avidin-HRP was added per well
and incubated at room temperature for 45 min. After washing the plates 3 times with ELISA/ELISPOT
washing buffer, 100 l of freshly prepared 3-amino-9-ethylcarbazole (AEC) substrate was added to each
well. Plates were left at room temperature until spots developed (approximately 3 to 5 min) and then
washed with water to stop the reaction. Plates were allowed to dry and then read in an ELISPOT plate
reader (Immunospot; CTL Europe GmbH, Bonn, Germany). Spots were counted using AID software
(Autoimmune Diagnostika, Germany). For analysis, the number of background spots (DMSO treated) was
subtracted from the number of spots detected in wells containing the p2 and p30 peptides.
CD4 T cell depletion and in vivo B cell proliferation and expansion assays. Tetanus-speciﬁc
CD4 T cells were depleted by 3 injections of puriﬁed anti-mouse CD4 antibody (GK1.5; BioLegend,
Germany). As described before (20), SW-HEL B-cells (unlabeled or labeled with CFSE) were transferred to
recipient BL/6 mice (3  106 to 5  106 cells per mouse) by intravenous (i.v.) injection. On the same day,
recipient mice were immunized with FrC-VLP-HEL containing FrC by i.v. injection at a ﬁnal dose of 100 ng HEL
per mouse. After 72 h, splenocytes were isolated and stained with HEL-Alexa 647 and B220 APC-eFluor780.
The CFSE ﬂuorescence intensity of CFSE HEL B220 cells was determined by ﬂow cytometry.
Analyses of humoral immune responses. Mice were bled by puncture of the retroorbital sinus with
a heparinized 10-l hematocrit capillary (Hirschmann Laborgerate, Eberstadt, Germany). The sera were
obtained after 5 min of centrifugation at 2,600  g in a tabletop centrifuge and stored at 20°C until
further use. Antibody responses against HIV-1 Gag and HIV-1 Env were determined by Ag-speciﬁc ELISA
as previously described (8). Brieﬂy, 96-well high-binding microtiter plates (Greiner Bio-One) were coated
with 200 ng glutathione S-transferase (GST)–Gag or 200 ng ConB gp120 in 0.1 mol bicarbonate buffer (pH
9.6) per well at room temperature overnight. After washing with PBS-T, the wells were blocked with 5%
skim milk powder in PBS-T and washed again before they were incubated with the various sera at
different dilutions in blocking buffer. After washing, bound antibodies were incubated with HRP-
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conjugated anti-mouse antibodies (P0447; DakoCytomation, Glostrup, Denmark) and washed exten-
sively. Bound HRP-conjugated antibodies were detected with an ECL solution composed of 5 ml Luminol
solution (3-aminophtolhydrazide; Sigma-Aldrich 09253-25G), 50 l solution B (p-coumaric acid; Sigma-
Aldrich C9008-5G), and 1.6 l 30% H2O2 (Merck KGaA, Darmstadt, Germany) in an Orion-96 microplate
reader (Berthold, Bad Wildbad, Germany). Humoral immune responses for Gag and tetanus toxoid are
expressed as log10-transformed relative light units (RLU). To determine Env-speciﬁc IgG1, IgG2a, IgG2b,
and IgG3 antibody concentrations, recombinant b12 antibodies containing the different Fc regions were
expressed in 293T cells and puriﬁed with protein G-Sepharose 4 Fast Flow instrument (GE Healthcare
Amersham, Darmstadt, Germany). After quantiﬁcation of the concentrations of the different b12 IgG subtypes
by a sandwich ELISA with AfﬁniPure goat anti-mouse IgG (Jackson ImmunoResearch, USA) as capture
antibody and HRP-labeled, polyclonal rabbit anti-mouse sera recognizing IgG1, IgG2a, IgG2b, and IgG3
(5300-01B; SouthernBiotech, Birmingham, USA) as detecting antibodies, they were used as standards in the
IgG subtype-speciﬁc Env ELISAs. Bound IgG1, IgG2a, IgG2b, or IgG3 antibodies were detected, after a washing
step, with HRP-conjugated Abs speciﬁc for each of the IgG subtypes (X56 and R19-15 from BD Biosciences,
Heidelberg, Germany, and SB74g and SB76b from Southern Biotech, Birmingham, AL, USA).
FcR activation assay. Activation of each murine Fc receptor (FcR) by the different immune sera
was analyzed as described previously (9). Brieﬂy, parental P815 cells and P815 Env cells expressing
ConB-gp140GC/D were incubated with 1:100 dilutions of the different sera in 100 l PBS for 30 min at
room temperature in a 96-well V-bottom plate. After a washing step with PBS, either mFcRII-CD3-,
mFcRIII-CD3-, or mFcRIV-CD3-transduced BW5147 reporter cells (9) were added in 100 l culture
medium and mixed, and the cocultures were incubated at 37°C in a humidiﬁed 5% CO2 atmosphere.
Eighteen hours later, 100 l PBS supplemented with 10% FCS and 0.1% Tween 20 was added to each well
and completely mixed to favor the release of murine IL-2 from the BW5147 cells. After 15 min of
incubation at room temperature, the cells were pelleted, and the IL-2 concentrations in the supernatants
were determined by ELISA with puriﬁed capture and biotinylated detection antibodies (BD Biosciences),
as previously described (9).
Ethics statement. All animal experiments performed during this study were approved by an external
ethics committee authorized by the North Rhine-Westphalia Ministry for Environment and Nature
Protection, Agriculture and Consumer Protection (licenses 84-02.2011.A111, 84-02.04.2012.A220 and
84-02.04.2013.A052). All mice were handled according to the instructions of the Federation of European
Laboratory Animal Science Association.
Statistical analysis. Quantitative summary data are shown as means standard errors of the means
(SEM). Statistical evaluation was performed with GraphPad Prism software version 6 using unpaired t
tests, one-way analysis of variance (ANOVA) with Tukey’s posttest, or the Kruskal-Wallis test with Dunn’s
posttest, as indicated in the ﬁgure legends.
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